Maxmarvil sales on the rise with added indications.

Published: 2006-02-23 06:58:00

Updated: 2006-02-23 06:58:00

Yuyu has changed the label of Maximarvil, an anti-osteoporosis drug, in which the patient may allow to lie down after medication of Maximarvil, which may increase its sales in such a severe market competition with many foreign multinational drug corporations, targeting more than 10 billion won of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK